- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03911440
Treatment and Vaccine Development of Mycoplasma Pneumoniae
April 9, 2019 updated by: National Taiwan University Hospital
Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development
A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Mycoplasma pneumoniae accounts for 10-30% of community-acquired pneumonia (CAP) in children.
Proportionally, M. pneumoniae has become the most important pathogen for childhood pneumonia after the widespread use of Streptococcus pneumoniae vaccines.
M. pneumoniae is routinely treated with antibiotics, and the macrolides antibiotics are the drug of choice for M. pneumonia infection.
However, macrolide-resistance rates have increased to 20 and 100% in Asia.
In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan.
The evolution and spreading of Mycoplasma in Taiwan and different countries are unknown.
While the macrolide-resistance is increasing, the optimal therapy remains unclear.
Both tetracyclines and fluoroquinolones showed promises in treating macrolide-resistant M. pneumoniae in adults.
However, their use in children is not recommended due to safety concerns.
Recently, evidence are accumulating that doxycycline, unlike other tetracyclines, does not cause staining of teeth.
In the current study, the investigators are going to carry out a randomized control trial to compare the efficacy and safety of doxycycline against macrolide-resistant M. pneumoniae.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Li-Min Huang, MD, PhD
- Phone Number: 71525 886-2-23123456
- Email: lmhuang@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 16 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Children aged 0-18 years, admitted due to lower respiratory tract infections. Mycoplamsa pneumonia is diagnosed.
- The diagnosis is made within 72 hours after fever onset.
- The patient and his/her guardians are willing to participate the study and able to follow the instruction.
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Azithromycin
Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
|
Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
|
Experimental: Doxycycline
Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
|
Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Defervescence
Time Frame: Up to 10 days
|
The timing (days) when fever subsides after treatment
|
Up to 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital stay
Time Frame: Up to 2 weeks
|
The length of hospitalization
|
Up to 2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 10, 2018
Primary Completion (Anticipated)
December 31, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
April 9, 2019
First Submitted That Met QC Criteria
April 9, 2019
First Posted (Actual)
April 11, 2019
Study Record Updates
Last Update Posted (Actual)
April 11, 2019
Last Update Submitted That Met QC Criteria
April 9, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Pleural Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pneumonia, Bacterial
- Pleurisy
- Mycoplasmatales Infections
- Pneumonia
- Pleuropneumonia
- Mycoplasma Infections
- Pneumonia, Mycoplasma
- Anti-Infective Agents
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Doxycycline
- Azithromycin
Other Study ID Numbers
- 201712045MINA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atypical Pneumonia
-
Professor Adrian CovicFalcon Trading Iasi; Romanian Academy of Medical SciencesUnknownCOVID-19 | Pneumonia, Viral | Pneumonia, Ventilator-Associated | Flu Symptom | Flu Like Illness | Influenza With Pneumonia | Pneumonia, Interstitial | Pneumonia AtypicalItaly, Romania, United Kingdom
-
PapiVax Biotech, Inc.ParexelRecruitingASC-US | LSIL | ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-Epithelial LesionUnited States
-
St. Jude Children's Research HospitalWithdrawnRhabdoid Tumor | CNS Tumor | Atypical Teratoid/Rhabdoid Tumor | Atypical Teratoid/Rhabdoid Tumor of CNSUnited States
-
Yeshiva UniversityYale UniversityRecruitingAnorexia Nervosa | Bulimia Nervosa | Anorexia Nervosa, Atypical | Bulimia; AtypicalUnited States
-
Centre Hospitalier Universitaire, AmiensCompletedAtypical; Mycobacterium, Pulmonary, TuberculousFrance
-
University of California, San DiegoRecruitingAnorexia Nervosa | Bulimia Nervosa | Atypical Anorexia Nervosa | Atypical Bulimia NervosaUnited States
-
University of Illinois at ChicagoTerminatedAtypical Mycobacterium Infections | Nontuberculous Mycobacterial DiseaseUnited States
-
University of Massachusetts, WorcesterAgency for Healthcare Research and Quality (AHRQ); Omnicare Clinical Research; Qualidi...CompletedOff-label Use of Atypical Antipsychotic DrugsUnited States
-
University of Sao PauloCompletedAtypical Facial Pain or Atypical OdontalgiaBrazil
-
OHSU Knight Cancer InstituteCompletedChronic Neutrophilic Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeUnited States
Clinical Trials on Azithromycin
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
Sheba Medical CenterUnknown
-
PfizerCompletedBacterial Infections
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
Emory UniversityThe Carter CenterSuspended
-
University of Alabama at BirminghamCompletedRespiratory Syncytial VirusUnited States